JP2014529395A5 - - Google Patents

Download PDF

Info

Publication number
JP2014529395A5
JP2014529395A5 JP2014523291A JP2014523291A JP2014529395A5 JP 2014529395 A5 JP2014529395 A5 JP 2014529395A5 JP 2014523291 A JP2014523291 A JP 2014523291A JP 2014523291 A JP2014523291 A JP 2014523291A JP 2014529395 A5 JP2014529395 A5 JP 2014529395A5
Authority
JP
Japan
Prior art keywords
dystonia
syndrome
disease
polynucleotide
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014523291A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014529395A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2014529395A publication Critical patent/JP2014529395A/ja
Publication of JP2014529395A5 publication Critical patent/JP2014529395A5/ja
Pending legal-status Critical Current

Links

JP2014523291A 2011-08-04 2012-07-26 ボツリヌス神経毒のタンパク質分解的切断の改変 Pending JP2014529395A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161574596P 2011-08-04 2011-08-04
EP11176531.9 2011-08-04
US61/574,596 2011-08-04
EP11176531 2011-08-04

Publications (2)

Publication Number Publication Date
JP2014529395A JP2014529395A (ja) 2014-11-13
JP2014529395A5 true JP2014529395A5 (enExample) 2016-07-28

Family

ID=47628649

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014523291A Pending JP2014529395A (ja) 2011-08-04 2012-07-26 ボツリヌス神経毒のタンパク質分解的切断の改変

Country Status (6)

Country Link
US (1) US20140170133A1 (enExample)
EP (1) EP2739297A1 (enExample)
JP (1) JP2014529395A (enExample)
AU (1) AU2012292163A1 (enExample)
CA (1) CA2841933A1 (enExample)
WO (1) WO2013017522A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3290437A1 (en) 2016-08-31 2018-03-07 Merz Pharma GmbH & Co. KGaA Novel recombinant clostridial neurotoxins with decreased duration of effect
EP3312193A1 (en) 2016-10-19 2018-04-25 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum neurotoxins with accelerated onset of effect
WO2018081282A1 (en) * 2016-10-25 2018-05-03 Cellsnap Llc Neurotoxins and uses thereof
EP3335719A1 (en) * 2016-12-14 2018-06-20 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum neurotoxins with a stabilized light chain
CN118126143B (zh) * 2024-03-14 2025-06-24 河北平朴生物科技合伙企业(有限合伙) 一种a型肉毒毒素的突变体及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939070A (en) * 1996-10-28 1999-08-17 Wisconsin Alumni Research Foundation Hybrid botulinal neurotoxins
US20030219462A1 (en) * 2000-07-21 2003-11-27 Allergan Sales, Inc Clostridial neurotoxin compositions and modified clostridial neurotoxins
US6903187B1 (en) * 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US6943555B2 (en) * 2002-05-23 2005-09-13 Lockheed Martin Corporation Redundant safety circuit for squib testing
JP5746624B2 (ja) * 2008-08-29 2015-07-08 メルツ・ファルマ・ゲーエムベーハー・ウント・コ・カーゲーアーアー 変化した持続性を有するクロストリジウム性神経毒
GB0903006D0 (en) * 2009-02-23 2009-04-08 Syntaxin Ltd Modified non-cytotoxic proteases

Similar Documents

Publication Publication Date Title
JP2009541396A5 (enExample)
JP2015536644A5 (enExample)
RU2015124069A (ru) Способы производства протеолитически процессированных полипептидов
JP5897784B2 (ja) ボツリヌス毒素の神経毒成分の高頻度適用
JP2014529395A5 (enExample)
Hackett Prolotherapy in whiplash and low back pain
RU2012103376A (ru) Биологическая активность
EP3600384A1 (en) Improved use of botulinum neurotoxin in the treatment of sialorrhea
JP2015504304A (ja) ポリ−グリシンを伴う修飾神経毒及びその使用
WO2022109304A1 (en) Systems, devices, and methods for gamma entrainment using haptic stimuli
WO2011160826A1 (en) Botulinum toxin therapy
US20120251574A1 (en) Endopeptidase and Neurotoxin Combination Treatment of Multiple Medical Conditions
US20120251575A1 (en) Endopeptidase Treatment of Involuntary Movement Disorders
RU2344805C2 (ru) Способ лечения заболеваний, травм периферической нервной системы, их последствий и последствий нарушения спинального мозгового кровообращения и спинальных травм
TAYLOR Fracture-dislocation of the neck: a method of treatment
Har-Shai et al. Lengthening temporalis myoplasty for facial palsy reanimation
Abdelghany et al. Effect of Instrument Assisted Soft Tissue Mobilization on Range of Motion in Children with Diplegic Cerebral Palsy: A Review Article
Guidubaldi et al. Clinical use of botulinum neurotoxin: neuromuscular disorders
RU2745475C1 (ru) Способ корректирующего массажа шейно-воротниковой зоны и плечевого пояса
Kay et al. Mobilization/Manipulation of the Cervical and Thoracic Spine (Techniques)
Strashko et al. Efficacy of the rehabilitation plan based on the theory of muscular spirals in patients with scapulohumeral pain syndrome according to shear wave elastography data
Olaru Introductory Chapter: Introduction to Rehabilitation
Elfiah et al. A COMBINATION OF CHEEK FLAP, CARTILAGE INSERTION, AND FAT TRANSFER ON POST-TRAUMA LOWER EYELID ECTROPION RECONSTRUCTION.
Sancheti et al. Efficacy of early community integration rehabilitation for cervical laminectomy: A case report
Farrell et al. Focal treatments, including botulinum toxin